Table 1.
Activity | Chrysin Treatment | Effects | Reference |
---|---|---|---|
Antioxidant | 20 mg/kg/30 days, p.o. | ↓ TBARS, lipid hydroperoxides, conjugated dienes tissue, circulatory levels ↑ SOD, CAT, GPx, Gsr activity, GSH, GSTs, vitamin C and vitamin E levels in ethanol-induced toxicity in rats |
[22] |
50 mg/kg/12 days, i.p. | ↑ GHS levels and CAT and SOD activity in heart homogenate in male rats | [27] | |
30 and 60 mg/kg/28 days, p.o. | ↑ NO and GHS levels, GSHPx, CAT, and SOD activity in rat heart homogenate | [28] | |
60 mg/kg/28 days, p.o | ↑ 8-OHdG, TBARS levels ↓ GSH, CAT, NO levels |
[29] | |
1 and 10 mg/kg/60 days, p.o. | ↑ SOD, CAT and GPx activity in PFC and HP of aged mice | [20] | |
1.25, 2.5, and 5 µM/30 min exposure | ↓ ROS formation in neuronal SH-SY5Y and microglial THP-1 cells in vitro | [30] | |
10, 30, and 100 mg/kg/44 days, p.o. | Protects against aluminum-induced oxidative stress by restored LPO levels and SOD and CAT activity in cortex and HP of male Swiss mice | [30] | |
Anti-inflammatory | 7.50, 4.75, and 120.90 µM, 18 h exposure | ↓ NO, PGE2 and TNF-α biosynthesis in CLP-induced RAW 264.7 cells |
[31] |
30 mg/kg/2 weeks, i.p. | ↓ ALT and AST activity ↓ TNF-α and IL-1β levels ↑ IL-10 and adiponectin in high-fat feeding mice |
[32] | |
25 and 50 mg/kg/12 days, i.p. | ↓ NF-κB, iNOS, COX-2, and TNF-α expression in heart homogenate of DOX-induced cardiotoxicity mice | [27] | |
30 and 60 mg/kg/28 days, p.o. | ↑ PPAR-γ and TGF-β expression ↓ NF-κBp65 and IKK-β expression and TNF-α level in heart homogenate of isoproterenol-induced myocardial injury rats |
[28,29] | |
5 and 20 mg/kg/28 days, p.o. | ↓ TNF-α, IL-1β and IL-6 levels in PFC and HP of chronically stressed mice | [18] | |
5 mg/kg/1 h before LP, i.p. | ↓ AST and TNF-α serum levels in septic mice survival | [33] | |
5 µM/24 h exposure | ↓ iNOS, IL-1β, and TNF-α expression in microglial THP-1 cells exposed to LPS | [30] | |
GABAergic/BZD | 3 µM, 60 min exposure | Acts as competitive ligand for central BZD site in bovine cerebral cortical membranes in vitro | [15] |
13 µM, 60 min exposure | Acts as competitive ligand for peripheral BZD binding site in rat kidneys membranes in vitro |
[15] | |
1 mg/kg, i.p. | Activates the GABAA/BZD receptor complex in male CF1 mice | [24] | |
1 mg/kg, i.p. | Activates the GABAA/BZD receptor complex in male Sprague Dawley rats | [17] | |
0.62 µM, 2 h exposure | Acts as competitive ligand for central BZD site in synaptosomal fractions of rat brain in vitro | [34] | |
10 and 30 µM, 30 s exposure | Modulates the activity of Cl− ion channel in the GABAA receptor expressed in Xenopus oocytes in vitro | [35] | |
2 mg/kg, i.p. | ↓ Anxiety-like behavior by modulating Cl− ion channel in the GABAA receptor of cycling female rats | [36] | |
2 mg/kg, i.p. | ↓ Depression-like behavior by modulating GABA-binding site in the GABAA receptor of ovariectomized female rats | [37] | |
0.5 µg/rat, i.h. | ↓ Anxiety-like behavior by modulating GABAA/BZD receptor complex in the dorsal hippocampus of cycling female rats | [14] | |
Serotonergic | 5 and 20 mg/kg, p.o. | ↑ 5-HT levels and 5-HIAA/5-HT ratio in HP of chronic stressed mice | [18] |
20 mg/kg/28 days, p.o. | ↑ 5-HT levels in PFC and HP in female mice with hypothyroidism | [12] | |
50 mg/kg twice a day per 4 days, p.o. | ↑ 5-HT levels in the striatum of the rat brain |
[38] | |
10 and 30 mg/kg/2 weeks, p.o. | ↑ 5-HT spinal levels ↓ 5-HIAA/5-HT ratio in male mice with experimental neuropathy |
[39] | |
5 mg/kg/28 days, i.p. | ↓ 5-HT1A receptor expression in the dorsal raphe ↑ 5-HT1A and 5-HT2A in the hippocampus of male rats |
[13] | |
Dopaminergic | 10 mg/kg/28 days, p.o | ↑ DA striatal levels in mice | [19] |
50, 100 and 200 mg/kg/5 days, p.o. | ↑ DA levels in striatum of mice treated with 1-methyl-1,2,3,6-tetrahidropidine |
[40] | |
20 mg/kg/28 days, p.o. | ↑ DA levels in PFC and HP in a hypothyroidism model in female mice | [12] | |
Noradrenergic | 50, 100 and 150 mg/kg, i.p. | ↓ NE serum levels in rats with pain induced by formalin |
[41] |
20 mg/kg/28 days, p.o. | No effects | [12] | |
Anti-apoptotic | 25 and 50 mg/kg/12 days, i.p. | ↓ Bax, caspase-3, and cytochrome c activity ↑ Bcl-2 expression in rat heart tissue extract |
[27] |
30 and 60 mg/kg/28 days, p.o. | ↑ Bcl-2 expression ↓ Bax and caspase-3 activity |
[29] | |
5 and 20 mg/kg/28 days, p.o. | ↓ Caspase-3 and caspase-9 activity in HP and PFC of chronically stressed mice | [18] | |
25, 50 and 100 mg/kg/3 days, p.o. | ↓ Apoptotic index in cerebral cortex and HP of rats with traumatic brain injury |
[42] | |
Neuroendocrine | 5 and 20 mg/kg/28 days, p.o. | ↓ Corticosterone plasma levels in chronically stressed mice | [11] |
5 and 20 mg/kg/28 days, p.o. | ↓ CRH and ACTH in chronically stressed mice | [18] | |
50, 100 and 150 mg/kg, i.p | ↓ Corticosterone serum levels in rats with pain induced by formalin | [41] | |
Neurotrophic | 5 and 20 mg/kg/28 days, p.o. | ↑ BDNF and NGF levels in PFC and HP in chronically stressed mice | [11] |
1 and 10 mg/kg/60 days, p.o. | ↑ BDNF levels in HP and PFC in aged mice | [20] | |
10 mg/kg/28 days, p.o. | ↑ BDNF and NGF levels in striatum in a Parkinson’s disease model in mice | [19] | |
20 mg/kg/28 days, p.o. | ↑ BDNF and NGF in HP and PFC in mice subjected to a hypothyroidism model | [43] |
TBARS = thiobarbituric acid reactive substance; SOD = superoxide dismutase; CAT = catalase; GPx = glutathione peroxidase; Gsr = glutathione reductase; GSTs = glutathione-S-transferase; GSH = reduced glutathione; NO = nitric oxide; GSHPx = plasma glutathione peroxidase; 8-OHdG = 8-hydroxy-2′-deoxyguanosine; PFC = prefrontal cortex; HP = hippocampus; ROS = reactive oxygen species; LPO = lipid peroxidation; PGE2 = prostaglandin E 2; TNF-α = tumor necrosis factor-α; CLP = cecal ligation and puncture procedure; ALT = alanine aminotransferase; AST = aspartate aminotransferase; IL-1β = interleukin 1 beta; IL-10 = interleukin 10; NF-κBp65 = nuclear transcription 116 factor kappa B heterodimer; iNOS = inducible nitric oxide synthase; COX- 2 = cyclooxygenase-2; DOX = doxorubicin; PPAR-γ = peroxisome proliferator-activated receptor-gamma; TGF-β = transforming growth factor-beta; IKK-β = inhibitor of nuclear factor kappa-B kinase subunit beta; IL-6 = interleukin-6; LPS = lipopolysaccharide; BZD = benzodiazepine; GABA = gamma-aminobutyric acid; 5-HT = 5-hydroxytriptamina, serotonin; 5-HIAA = 5-hydroxyindoleacetic; 5-HT1A = serotonin 1A receptor; 5-HT2A = serotonin 2A receptor; DA = dopamine; NE = noradrenaline; BAX = pro-apoptotic protein of the subfamily Bax; Bcl-2 = B-cell lymphoma-2; CRH = corticotropin-releasing hormone; ACTH = adrenocorticotropic hormone; BDNF = brain-derived neurotrophic factor; NGF = nerve growth factor; ↑ = increase; ↓ = decrease; p.o. = per oral route; i.p. = intraperitoneal injection; i.h. = intrahippocampal microinjection. (Table was prepared by the authors).